Genesis of Alzheimer's disease

Neurology

Volumn 48, Issue 5 SUPPL. 7, 1997, Pages

  Whitehouse, Peter J ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CHOLINESTERASE INHIBITOR; DONEZEPIL; ESTROGEN; FREE RADICAL; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; NICOTINE; PROPENTOFYLLINE; SABELUZOLE; SCAVENGER; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; HUMAN; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0030949664     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.5_suppl_7.2s     Document Type: Article

References (59)

1. Scadding JG. Essentialism and nominalism in medicine: logic of diagnosis in disease terminology. Lancet 1996;348:594-596.
2. Beyreuther K, Masters CL. Neurodegeneration and dementia: Alzheimer's disease as a model. Arzneimittelforschung 1995; 45:347-350.
3. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994;15:447-450.
4. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995;10:509-519.
5. Mayeux R. Understanding Alzheimer's disease: expect more genes and other things. Ann Neurol 1996;39:689-690.
6. Price DL, Sisodia SS. Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 1994;45: 435-446.
7. Mann DMA. How genetic causes of Alzheimer's disease further our understanding of its pathogenesis. Alzheimer Res 1995;1:117-122.
8. Smith C, Anderton BH. Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process? Neuropathol Appl Neurobiol 1994;20:322-338.
9. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172-176.
10. Selkoe DJ. Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem 1996;271:18295-18298.
11. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-432.
12. van Duijn CM, Havekes LM, Van Broeckhoven C, de Knijff P, Hofman A. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. Br Med J 1995;310:627-631.
13. 12a. Kalariá RN. Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Neurobiol Aging 1996;17: 687-693.
14. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:1:75-83.
15. Ford AB, Mefrouche Z, Friedland RP, Debanne SM. Smoking and cognitive impairment: a population-based study. J Am Geriatr Soc 1996;44:905-909.
16. Whitehouse PJ, Kalaria RN. Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. Alzheimer Dis Assoc Disord 1995;9:2:3-5.
17. Lerner AJ, Koss E, Gilham S, et al. Estrogen replacement therapy as a protective factor for Alzheimer disease: interactions with other risk factors [abstract]. Soc Neurosci 1996;22: 15.
18. Berg JM, Karlinsky H, Holland AJ, eds. Alzheimer disease, Down syndrome, and their relationship. Oxford: Oxford University Press, 1993.
19. Goate AM, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706.
20. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992;258:668-671.
21. St. George-Hyslop PH, Haines J, Rogaev EI, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nature Genet 1992;2:330-334.
22. Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1 type familial Alzheimer disease. Ann Neurol 1996;40:932-936.
23. Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996;5:985-988.
24. Younkin SG. Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol 1995;37:287-288.
25. Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L, Gambetti P. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994;200:1598-1603.
26. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
27. 42 in neocortical and cerebrovascular amyloid β deposits in Swedish familial Alzheimer's disease and Down's syndrome. Neuro Rep 1996;7:1377-1381.
28. Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on ApoE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429-437.
29. Cordell B, Higgins LS, Higaki J, Zhong Z, Moran PM, Moser PM. A model of β-amyloid formation and Alzheimer's disease. Alzheimer Res 1995;1:3:111-116.
30. Cole GM, Yang F, Frautschy SA, Saido TC, Hsiao K. Development of β-amyloid plaques in hu APP695.SWE transgenic mice [abstract]. Soc Neurosci 1996;22:24.
31. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med 1996;2:93-95.
32. Mattson MP. Calcium and neuronal injury in Alzheimer's disease: contributions of beta-amyloid precursor protein mismetabolism, free radicals, and metabolic compromise. Ann NY Acad Sci 1994;15:50-76.
33. Mrak RE, Sheng JG, Griffin WS. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol 1995;26:816-823.
34. Yen SH, Liu WK, Hall FL, Yan SD, Stern D, Dickson DW. Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging 1995; 16:3:381-387.
35. Giaccone G, Pedrotti B, Migheli A, et al. β-PP and tau interaction: a possible link between amyloid and neurofibrillary tangles in Alzheimer s disease. Am J Pathol 1996;148:79-87.
36. Larner AJ. The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis. Dementia 1995;6:218-224.
37. Fisher A, Barak D. Progress and perspectives in new muscarinic agonists. DN&P 1994;7:453-464.
38. Hoover TM. CI-979/RU 35926: a novel muscarinic agonist for the treatment of Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;239-243.
39. Bodick N, Offen W, Rasmussen K, Paul S. The effects of xanomeline, an M1-selective muscarinic agonist, on behavioral symptoms in Alzheimer's disease. Presented at the Fifth International Conference on Alzheimer's Disease and Related Disorders, July 24-29, 1996, Osaka.
40. Schwarz RD, Callahan MJ, Davis RE, et al. Selective muscarinic agonists for Alzheimer disease treatment. Alzheimer Dis Assoc Disord 1994;224-228.
41. Shimohama S, Matsushima H. Signal transduction mechanisms in Alzheimer disease. Alzheimer Dis Assoc Disord 1995; 9:15-22.
42. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988;24: 233-242.
43. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci 1992;13:439-445.
44. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med 1996;335:330-336.
45. Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 1996;348:94-97.
46. Nordberg A. In vivo detection of neurotransmitter changes in Alzheimer's disease. Ann NY Acad Sci 1993;695:27-33.
47. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 1986; 261:6084-6089.
48. Hock C, Golombowski S, Naser W, Muller-Spahn F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol 1995;37:414-415.
49. Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett 1995; 186:189-191.
50. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186: 181-183.
51. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Am Neurol Assoc 1995;38:643-648.
52. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1994;38:6-14.
53. Breitner JSC. ApoE genotyping and Alzheimer's disease. Lancet 1996;347:1184-1185.
54. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG, eds. Assessing genetic risks: implications for health and social policy. Washington: National Academy Press, 1994.
55. Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995; 274:1627-1629.
56. Saunders AM, Hulette C, Welsh KA, et al. Specificity, sensitivity and predictive value of apolipoprotein E genotyping in a consecutive autopsy series of sporadic Alzheimer disease. Lancet 1996;348:90-93.
57. Post SG. Genetics, ethics, and Alzheimer disease. J Am Genatr Soc 1994;42:782-786.
58. Bird TD. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease: a cautionary view. Ann Neurol 1995;38:2-4.
59. Mayeux R, Schupf N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 1995;85:1280-1284.